Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
2.990
+0.180 (6.41%)
At close: Dec 20, 2024, 4:00 PM
3.050
+0.060 (2.01%)
After-hours: Dec 20, 2024, 5:34 PM EST
Company Description
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.
The company’s lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Inozyme Pharma, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Douglas Treco |
Contact Details
Address: 321 Summer Street, Suite 400 Boston, Massachusetts 02210 United States | |
| Phone | 857 330 4340 |
| Website | inozyme.com |
Stock Details
| Ticker Symbol | INZY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001693011 |
| CUSIP Number | 45790W108 |
| ISIN Number | US45790W1080 |
| Employer ID | 47-5129768 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Douglas A. Treco Ph.D. | Chief Executive Officer and Chairman |
| Axel Bolte M.B.A., M.Sc. | Co-Founder, Senior Advisor and Director |
| Sanjay S. Subramanian M.B.A., M.S. | Senior Vice President, Chief Financial Officer, Principal Accounting Officer and Corporate Secretary |
| Dr. Matthew Winton Ph.D. | Senior Vice President and Chief Operating Officer |
| Dr. Demetrios Braddock M.D., Ph.D. | Co-Founder, Scientific Founder, Member of Scientific Advisory Board and Board Observer |
| Dr. Soojin Kim Ph.D. | Senior Vice President and Chief Technical Operations Officer |
| Dr. David Thompson M.A., M.S., Ph.D. | Senior Vice President, Chief Scientific Officer and Chief Development Officer |
| Stefan Riley | Director of Investor Relations |
| Gayle Gironda | Senior Vice President and Chief People Officer |
| Dr. Yves Sabbagh Ph.D. | Chairman of Scientific Advisory Board and Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 7, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 424B5 | Filing |